How do herpangina and influenza differ in presentation and management?

Herpangina and Influenza: Key Clinical Distinctions

Herpangina and influenza are fundamentally different diseases requiring distinct diagnostic and management approaches—herpangina is an enteroviral infection characterized by posterior pharyngeal vesicles requiring only supportive care, while influenza is a respiratory viral illness that may warrant antiviral therapy in high-risk patients.

Clinical Presentation Differences

Herpangina

• Characteristic pharyngeal lesions: Painful vesicles and ulcers localized to the posterior pharynx, soft palate, and tonsillar pillars 1
• Causative agents: Primarily Coxsackievirus-A, Enterovirus-A, and Echovirus 1
• Typical course: Self-limited illness lasting 4-6 days with excellent prognosis 1
• Age distribution: Predominantly affects young children 1

Influenza

• Respiratory symptoms predominate: Fever, cough, and rhinorrhea are the most common presenting features 2
• Age-specific presentations vary significantly:
  • Neonates: Non-specific signs including pallor, lethargy, poor feeding, apnea; fever may be the only feature 2
  • Infants and children <2 years: Fever alone is common, with gastrointestinal symptoms (diarrhea, vomiting) more frequent than in older children; febrile convulsions are positively associated with influenza A 2
  • Older children: Pharyngitis and headache are frequent symptoms 2
• Gastrointestinal involvement: Present in a relatively large proportion of cases, contrasting with seasonal influenza patterns 2

Diagnostic Approach

Herpangina

• Clinical diagnosis: Based on epidemiological history, typical symptoms, and characteristic posterior pharyngeal damage 1
• Virological testing: Available but diagnosis can be rendered clinically 1

Influenza

• Clinical diagnosis is sufficient: The decision to begin antiviral therapy should not be delayed for laboratory confirmation 3
• Testing recommendations for severe cases: Nucleic acid amplification test (NAAT) is recommended for suspected severe influenza 4, 5
• Testing for non-severe cases: NAAT or digital immunoassay (DIA) may be used 4, 5

Management Strategies

Herpangina

• Supportive care only: Treatment is mainly symptomatic 1
• Topical therapy: Oral spray with antiviral drugs may be incorporated 1
• No systemic antivirals indicated: Self-limited course does not warrant aggressive intervention 1

Influenza Management

Non-Severe Influenza

• Baloxavir conditionally recommended if the patient is at high risk of severe illness (within 48 hours of symptom onset) 4, 5
• No antivirals recommended if risk of severe illness is low 4, 5
• Strong recommendation against antibiotics if bacterial co-infection is unlikely 4, 5

Severe Influenza

• Oseltamivir conditionally recommended for severe influenza 4, 5
• Dosing for children over 1 year:
  • <15 kg (<3 years): 30 mg every 12 hours 2
  • 15-23 kg (3-7 years): 45 mg every 12 hours 2
  • ≥24 kg (>7 years): 75 mg every 12 hours 2
• Extended treatment window: In severely ill hospitalized children, oseltamivir may be used if symptomatic for less than 6 days 2

Prophylaxis Considerations

• Baloxavir, laninamivir, oseltamivir, or zanamivir conditionally recommended for asymptomatic persons exposed to seasonal influenza who are at extremely high risk of hospitalization 4, 5
• For zoonotic influenza exposure: Prophylaxis recommended regardless of individual risk 4, 5

Adjunctive Therapies

• Conditional recommendations against in severe influenza: corticosteroids, macrolides (without co-infection), mTOR inhibitors, and passive immune therapy 4, 5
• Antipyretics and analgesics appropriate for symptom management (pain, fever) 2

Complications and Risk Stratification

Herpangina

• Minimal complications: Generally benign course 1

Influenza

• High-risk groups requiring close monitoring 2:

  • Children with underlying respiratory or cardiac disease
  • Immunocompromised patients
  • Non-ambulant children
  • Younger children (especially <2 years have 12-times higher admission rates than 5-17 year olds) 2

• Life-threatening complications to recognize 2:

  • Bacterial pneumonia (most common)
  • Acute respiratory distress syndrome
  • Encephalopathy or encephalitis presenting as seizures or altered mental status

• Secondary bacterial infections: Particularly pneumonia and otitis media are common; oseltamivir reduces otitis media incidence from 21% to 12% 2

Critical Pitfalls to Avoid

• Do not confuse posterior pharyngeal vesicles (herpangina) with the diffuse pharyngitis of influenza—the anatomic distribution is diagnostically crucial 1, 2
• Do not delay antiviral therapy in high-risk influenza patients waiting for laboratory confirmation 3
• Do not prescribe antibiotics empirically for influenza unless bacterial co-infection is suspected 4, 5
• Do not use oseltamivir beyond 48 hours in non-severe community cases unless the patient is severely ill and hospitalized (then up to 6 days) 2, 4